Heber Reyes, Medical Oncologist at ISSSTE, shared a post on X:
“Very favorable risk! Congratulations again to Martín Zarbá and the entire IMDC for a new prognostic definition in decision-making for patients with advanced renal cancer.
OncoDaily, Keep on keeping on!”
Quoting Daniel Heng, Head of Medical Oncology at the Arthur J.E. Child Comprehensive Cancer Centre in Calgary, Alberta, shared on X:
“Just Out: Couldn’t have said it better. Very Favorable risk is a new category of metastatic kidney cancer that needs VEGF-based therapy. IO alone may not be enough. Great work Martín Zarbá, Toni Choueiri, Tom Powles, Rana McKay, Eddy Saad, UCalgaryMedicine, JAMA Network Open.”
Title: Clinical and Molecular Validation of the Very Favorable IMDC Risk Group in Metastatic Renal Cell Carcinoma
Authors: Martin Zarba, Eddy Saad, Karl Semaan, Talal El Zarif, Evan Ferrier, Connor Wells, Razane El Hajj Chehade, Naveen S. Basappa, Hedyeh Ebrahimi, Mahrukh Huseni, Romain Banchereau, Rana R. McKay, Lori Wood, Benoit Beuselinck, Cristina Suárez, Kosuke Takemura, Aly-Khan A. Lalani, Haoran Li, Lavinia Anne Spain, Arnoud J. Templeton, Thomas B. Powles, Georg A. Bjarnason, Guillermo de Velasco, Toni K. Choueiri, Daniel Y. C. Heng.
Other articles featuring Heber Reyes and Daniel Heng on OncoDaily.